SYDNEY, May 17, 2016 /PRNewswire/ -- Benitec
Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today
announced that the Company will host a conference call and live
audio webcast on Wednesday, 25 May
2016 at 8:00am AEST / Tuesday,
24 May 2016 at 6:00pm EDT, to provide its quarterly operational
update. Interim CEO, Greg West, will
provide an overview of Benitec's current and planned corporate and
clinical activities.
Conference Call and Webcast Information:
To access the live webcast please enter
http://services.choruscall.com/links/bntc160523 into your internet
browser. Investors will be able to submit questions in writing via
the webcast, to be addressed by Benitec's management during the
call.
To access the conference call, please use the dial in details
below.
Conference ID: 902026
US dial in: +1 855-624-0077
Australia dial in: 1800
908 299 or 1800 455 963
All other locations dial: +61 2 9007 8048
Shareholders are encouraged to use the webcast link, as
conference call lines are limited. An archive of the
webcast will remain available on Benitec's website for 90 days
beginning at approximately 9:30am
AEST on 25 May 2016.
For further information regarding Benitec and its activities,
please contact the persons below, or visit the Benitec website at
www.benitec.com
Australia
Investor Relations
|
|
|
|
United States
Investor Relations
|
|
|
|
|
|
MarketEye
Orla
Keegan
Director
Tel: +61 (2) 8097
1201
Email:
orla.keegan@marketeye.com.au
|
|
|
|
PCG Advisory
Group
Adam
Holdsworth
Managing Director of
Investor Relations
Tel: + 1
646-862-4607
Email:
adamh@pcgadvisory.com
Sean Leous
Managing Director of
Public Relations
Tel: +1
646-863-8998
Email:
sleous@pcgadvisory.com
|
About Benitec Biopharma Limited:
Benitec
Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a
biotechnology company developing innovative therapeutics based on
its patented gene-silencing technology called ddRNAi or 'expressed
RNAi'. Based in Sydney, Australia
with labs in Hayward, CA (USA) and
collaborators and licensees around the world, the company is
developing ddRNAi-based therapeutics for chronic and
life-threatening human conditions including hepatitis B, wet
age-related macular degeneration and OPMD. Benitec has also
licensed ddRNAi to other biopharmaceutical companies for
applications including HIV/AIDS, Huntington's Disease, chronic
neuropathic pain and retinitis pigmentosa.
Safe Harbor Statement:
This press release
contains "forward-looking statements" within the meaning of section
27A of the US Securities Act of 1933 and section 21E of the US
Securities Exchange Act of 1934. Any forward-looking statements
that may be in the press release are subject to risks and
uncertainties relating to the difficulties in Benitec's plans to
develop and commercialize its product candidates, the timing of the
initiation and completion of preclinical and clinical trials, the
timing of patient enrolment and dosing in clinical trials, the
timing of expected regulatory filings, the clinical utility and
potential attributes and benefits of ddRNAi and Benitec's product
candidates, potential future out-licenses and collaborations, the
intellectual property position and the ability to procure
additional sources of financing. Accordingly, you should not rely
on those forward-looking statements as a prediction of actual
future results.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/benitec-biopharma-to-host-corporate-update-conference-call-300269749.html
SOURCE Benitec Biopharma Limited